Location History:
- Wiesbaden, DE (1985 - 1993)
- Hofheim, DE (1997 - 2003)
- Hogheim, DE (2004)
- Hofheim am Taunus, DE (2005)
- Frankfurt-am-Main, DE (2014 - 2017)
Company Filing History:
7 out of 6,662 
4 out of 330 
2 out of 1,829 
Years Active: 1985-2017
Title: Gerhard Seipke: Innovator in Insulin Derivatives
Introduction
Gerhard Seipke is a prominent inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of insulin derivatives. With a total of 13 patents to his name, Seipke's work has had a profound impact on diabetes treatment.
Latest Patents
Seipke's latest patents focus on novel insulin analogs that exhibit an extremely delayed time-action profile. One of his inventions relates to insulin derivatives characterized by specific features, including an amidated basic amino acid residue at the B chain end, a lysine or arginine radical at the N-terminal amino acid residue of the insulin A chain, and various substitutions of negatively charged amino acid residues. Another patent also addresses insulin derivatives with delayed action, emphasizing the addition and substitution of charged amino acid residues and the amidation of the C-terminal carboxy group of the B chain.
Career Highlights
Throughout his career, Gerhard Seipke has worked with notable companies in the pharmaceutical industry. He has been associated with Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH, where he contributed to advancements in insulin research and development.
Collaborations
Seipke has collaborated with esteemed colleagues in his field, including Paul Habermann and Johann Ertl. Their combined expertise has furthered the understanding and innovation in insulin therapies.
Conclusion
Gerhard Seipke's contributions to the field of insulin derivatives have established him as a key figure in biochemistry. His innovative patents and collaborations continue to influence diabetes treatment and research.